Quick Read
- Metformin lowers blood sugar by suppressing Rap1 protein in the brain’s ventromedial hypothalamus.
- Activation of SF1 neurons in the brain is essential for metformin’s antidiabetic effects.
- Mice lacking Rap1 do not respond to low doses of metformin, confirming brain dependency.
- Direct brain delivery of metformin reduces blood sugar at much lower doses than oral intake.
- Discovery opens potential for new diabetes drugs targeting brain pathways and expanded uses in aging and brain health.
HOUSTON (Azat TV) – A groundbreaking study from Baylor College of Medicine published on March 25, 2026, reveals that metformin, the cornerstone drug for type 2 diabetes treatment for over six decades, works not only by affecting the liver and gut but also directly through a specific brain pathway. This discovery fundamentally changes the understanding of how metformin regulates blood sugar and could lead to a new generation of diabetes drugs with improved precision and fewer side effects.
Metformin’s Brain Mechanism: The Role of Rap1 Protein in Diabetes Control
Metformin has been prescribed worldwide since the 1950s for its effectiveness in lowering blood glucose, but until now, its full mechanism remained partially mysterious. Researchers led by Dr. Makoto Fukuda identified a small protein called Rap1 located in the ventromedial hypothalamus (VMH) of the brain as a critical mediator of metformin’s blood sugar-lowering effects. The VMH is a key brain region involved in metabolic regulation.
The study found that when Rap1 is active, blood sugar levels remain elevated. Metformin suppresses Rap1 activity, which in turn lowers blood glucose. Crucially, mice genetically engineered to lack Rap1 in the VMH showed no response to low doses of metformin, confirming that this brain pathway is essential for the drug’s action at clinically relevant doses.
Activation of SF1 Neurons Links Metformin to Neural Circuits
The research also identified that metformin activates specific neurons in the VMH called SF1 neurons, but only when Rap1 is present. These neurons increase electrical activity in response to metformin, providing a direct neural circuit through which the drug modulates metabolism. This level of specificity is unprecedented for a medication developed over 60 years ago and opens doors to more targeted therapies.
Implications Beyond Diabetes: Potential for Brain Health and Aging
Metformin’s benefits may extend beyond glucose control. The drug is increasingly recognized for its potential neuroprotective effects, including slowing biological aging, reducing DNA damage, and possibly protecting against long COVID. A 2025 study showed that women on metformin had a 30% lower risk of dying before age 90 compared to those on other diabetes medications, reinforcing its geroprotective properties.
The newly discovered brain pathway involving Rap1 could underlie these broader effects, suggesting that metformin’s influence on brain function contributes to its wide-ranging health impacts. Researchers are now investigating whether targeting this brain pathway could enhance metformin’s efficacy and expand its use to treat other brain-related conditions.
Future Directions: Toward Brain-Targeted Diabetes Therapies
The discovery challenges the long-held view that metformin acts primarily through the liver and gut, highlighting the brain’s critical role in metabolic control. Delivering very low doses of metformin directly into the brain of diabetic mice resulted in significant blood sugar reductions, demonstrating the brain’s high sensitivity to the drug.
Researchers envision developing new diabetes medications that specifically target the Rap1 pathway in the brain. Such drugs could achieve better blood sugar control with fewer gastrointestinal side effects common to metformin, such as nausea and diarrhea. Clinical trials in humans are needed to validate these findings and explore the therapeutic potential for brain-related diseases and aging.
Despite metformin’s decades-long use, this discovery marks a paradigm shift, showing that even well-established drugs can reveal unexpected mechanisms decades later, revolutionizing treatment approaches for millions of people worldwide.
This breakthrough highlights the importance of revisiting established medications with modern neuroscience tools, revealing complex interactions between brain and body that reshape our understanding of metabolic diseases and aging.